174 related articles for article (PubMed ID: 26553387)
1. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.
Yadav P; Masroor M; Tanwer K; Mir R; Javid J; Ahmad I; Zuberi M; Kaza RC; Jain SK; Khurana N; Ray PC; Saxena A
Clin Transl Oncol; 2016 Jul; 18(7):728-34. PubMed ID: 26553387
[TBL] [Abstract][Full Text] [Related]
2. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
[TBL] [Abstract][Full Text] [Related]
3. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
[TBL] [Abstract][Full Text] [Related]
6. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Sinilnikova OM; Antoniou AC; Simard J; Healey S; Léoné M; Sinnett D; Spurdle AB; Beesley J; Chen X; ; Greene MH; Loud JT; Lejbkowicz F; Rennert G; Dishon S; Andrulis IL; ; Domchek SM; Nathanson KL; Manoukian S; Radice P; Konstantopoulou I; Blanco I; Laborde AL; Durán M; Osorio A; Benitez J; Hamann U; Hogervorst FB; van Os TA; Gille HJ; ; Peock S; Cook M; Luccarini C; Evans DG; Lalloo F; Eeles R; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Brewer C; ; Hughes DJ; Coupier I; Giraud S; Coulet F; Colas C; Soubrier F; Rouleau E; Bièche I; Lidereau R; Demange L; Nogues C; Lynch HT; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Sutter C; Deissler H; Schaefer D; Froster UG; ; Aittomäki K; Nevanlinna H; McGuffog L; Easton DF; Chenevix-Trench G; Stoppa-Lyonnet D;
Br J Cancer; 2009 Oct; 101(8):1456-60. PubMed ID: 19707196
[TBL] [Abstract][Full Text] [Related]
7. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
8. Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population.
Yilmaz M; Tas A; Donmez G; Kacan T; Silig Y
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1059-1062. PubMed ID: 29699057
[TBL] [Abstract][Full Text] [Related]
9. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
[TBL] [Abstract][Full Text] [Related]
10. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
11. Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.
Thurow HS; Hartwig FP; Alho CS; Silva DS; Roesler R; Abujamra AL; de Farias CB; Brunetto AL; Horta BL; Dellagostin OA; Collares T; Seixas FK
Mol Biol Rep; 2013 Aug; 40(8):4929-34. PubMed ID: 23661019
[TBL] [Abstract][Full Text] [Related]
12. A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
Alshatwi AA; Hasan TN; Shafi G; Alsaif MA; Al-Hazzani AA; Alsaif AA
Fundam Clin Pharmacol; 2012 Jun; 26(3):438-43. PubMed ID: 21477265
[TBL] [Abstract][Full Text] [Related]
13. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.
Cai X; Yang M
J Cancer Res Clin Oncol; 2012 Apr; 138(4):555-61. PubMed ID: 22205265
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study.
Zhang Y; Liu L; Tang Y; Chen C; Wang Q; Xu J; Yang C; Miao X; Wei S; Chen J; Nie S
Mol Biol Rep; 2012 Oct; 39(10):9661-8. PubMed ID: 22744426
[TBL] [Abstract][Full Text] [Related]
15. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
16. The role of TP53 and MDM2 polymorphisms in TP53 mutagenesis and risk of non-melanoma skin cancer.
Almquist LM; Karagas MR; Christensen BC; Welsh MM; Perry AE; Storm CA; Nelson HH
Carcinogenesis; 2011 Mar; 32(3):327-30. PubMed ID: 21123835
[TBL] [Abstract][Full Text] [Related]
17. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
[TBL] [Abstract][Full Text] [Related]
18. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.
Faur N; Araud L; Laroche-Clary A; Kanno J; Toutain J; Yamori T; Robert J; Le Morvan V
Br J Cancer; 2009 Jul; 101(2):350-6. PubMed ID: 19513075
[TBL] [Abstract][Full Text] [Related]
19. Association of genetic polymorphisms in MDM2, PTEN and P53 with risk of esophageal squamous cell carcinoma.
Ma J; Zhang J; Ning T; Chen Z; Xu C
J Hum Genet; 2012 Apr; 57(4):261-4. PubMed ID: 22336889
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
